Jinhao94
2021-12-17
Pls like
CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&J)</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690543539,"tweetId":"690543539","gmtCreate":1639697065409,"gmtModify":1639697065650,"author":{"id":3564660171292335,"idStr":"3564660171292335","authorId":3564660171292335,"authorIdStr":"3564660171292335","name":"Jinhao94","avatar":"https://static.tigerbbs.com/acdaf2c50efc732ad49148e15b3d4a6a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pls like</p></body></html>","htmlText":"<html><head></head><body><p>Pls like</p></body></html>","text":"Pls like","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690543539","repostId":1154960652,"repostType":4,"repost":{"id":"1154960652","kind":"news","pubTimestamp":1639695603,"share":"https://www.laohu8.com/m/news/1154960652?lang=zh_CN&edition=full","pubTime":"2021-12-17 07:00","market":"us","language":"en","title":"CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&J)</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1154960652","media":"The Wall Street Journal","summary":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moder","content":"<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司(Pfizer Inc.)PFE 4.17%或Moderna Inc.mRNA-0.44%的Covid-19疫苗，而强生公司(Johnson&Johnson)JNJ 1.09%的疫苗，此前卫生当局表示，一种罕见但严重的凝血疾病的发生率高于之前检测到的。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>周四，免疫实践咨询委员会在听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况后，以15比0的投票结果提出了这一建议。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生疫苗的使用造成另一个打击，强生疫苗的使用因制造问题和早期有关凝血状况的报道而受到损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>CDC官员周四表示，在美国J&J疫苗接种者中，至少有54例血栓形成伴血小板减少综合征（TTS）病例，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们表示，男性和女性的病例率都高于之前的估计，而且年龄范围也更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“我只是不能推荐与可能导致死亡的疾病相关的疫苗，”俄亥俄州哥伦布市俄亥俄州立大学全国儿童医院的儿科传染病专家、委员会成员巴勃罗·桑切斯说。</blockquote></p><p> J&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.</p><p><blockquote>强生表示，对其疫苗的总体积极效益风险状况仍然充满信心。强生制药研发全球主管Mathai Mammen表示：“使用强生疫苗的人的安全和福祉仍然是我们的首要任务。”</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他表示，该公司将与疾病预防控制中心合作采取下一步措施，并强烈支持有关TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生的Covid-19疫苗基于与辉瑞和Moderna疫苗中使用的信使RNA不同的技术。</blockquote></p><p> J&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生的疫苗包括一种可导致普通感冒的无害版本的病毒，该病毒被设计成包含引发针对冠状病毒的免疫反应的基因指令。mRNA疫苗不含任何病毒物质，并使用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查TTS病情时暂停了强生疫苗的使用。在卫生当局得出结论认为疫苗的益处仍然大于风险后，该疫苗的使用于四月份恢复。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为CDC提供疫苗政策建议的ACIP在召开两次会议讨论该问题后，于4月份投票决定恢复使用强生的疫苗。向疫苗提供者和接受者提供的情况说明书中添加了有关风险的警告，包括30至49岁女性的风险似乎最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>截至8月31日，CDC官员在顾问会议上表示，在所有接种者中，每接种100万剂强生疫苗，就会报告约3.8例TTS病例。30至39岁女性的比率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>CDC官员还表示，在那些患TTS的人中，死亡率约为15%。官员称，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>CDC官员表示，接种强生的疫苗仍然优于不接种疫苗，但辉瑞-BioNTech和Moderna的信使RNA疫苗的益处和风险之间的平衡优于强生。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP的建议对疫苗提供者或接受者没有约束力，但它将具有重大影响力，因为该委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，J&J疫苗应该继续提供给无法接种mRNA疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或对一定剂量的疫苗有严重过敏反应的人，不应接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗也有引起包括心肌炎在内的心脏炎症的风险，特别是在30岁以下的男性中。然而卫生官员表示，预防Covid-19住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>强生疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监测疫苗的安全性，包括TTS风险。她说，这种疫苗是拯救生命的工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分出于安全考虑，强生的单剂疫苗的使用量远低于Moderna和辉瑞及其合作伙伴BioNTech SE的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.</p><p><blockquote>据CDC称，美国约有1610万人接种了强生疫苗。强生疫苗已接种约87万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗和2400万剂Moderna加强剂。</blockquote></p><p> J&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生周四表示，最近更新了其疫苗的情况说明书，称不应将其注射给在接受过先前剂量的强生疫苗或其他具有类似腺病毒设计的疫苗后曾出现TTS的人。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他具有类似设计的疫苗包括阿斯利康公司的Covid-19疫苗，该疫苗在美国以外有售，但在美国没有。</blockquote></p><p> The recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.</p><p><blockquote>该建议可能会影响美国以外对强生疫苗的支持，包括在努力增加剂量供应的国家，就在强生开始运送默克公司帮助生产的疫苗之际。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.</p><p><blockquote>CDC咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是此举可能会削弱人们对强生疫苗的信心，而不是mRNA疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&J)</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s<blockquote>CDC顾问推荐辉瑞(Pfizer)和Moderna Covid-19疫苗而不是强生(J&J)</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-12-17 07:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p><p><blockquote>美国疫苗顾问建议成年人接种辉瑞公司(Pfizer Inc.)PFE 4.17%或Moderna Inc.mRNA-0.44%的Covid-19疫苗，而强生公司(Johnson&Johnson)JNJ 1.09%的疫苗，此前卫生当局表示，一种罕见但严重的凝血疾病的发生率高于之前检测到的。</blockquote></p><p> The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p><p><blockquote>周四，免疫实践咨询委员会在听取了疾病控制和预防中心官员关于强生疫苗接种者出现血栓和血小板水平低的报告的最新情况后，以15比0的投票结果提出了这一建议。</blockquote></p><p> The updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p><p><blockquote>更新后的立场可能会对强生疫苗的使用造成另一个打击，强生疫苗的使用因制造问题和早期有关凝血状况的报道而受到损害。</blockquote></p><p> There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p><p><blockquote>CDC官员周四表示，在美国J&J疫苗接种者中，至少有54例血栓形成伴血小板减少综合征（TTS）病例，其中9例导致死亡。</blockquote></p><p> The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p><p><blockquote>官员们表示，男性和女性的病例率都高于之前的估计，而且年龄范围也更广。</blockquote></p><p> “I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p><p><blockquote>“我只是不能推荐与可能导致死亡的疾病相关的疫苗，”俄亥俄州哥伦布市俄亥俄州立大学全国儿童医院的儿科传染病专家、委员会成员巴勃罗·桑切斯说。</blockquote></p><p> J&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.</p><p><blockquote>强生表示，对其疫苗的总体积极效益风险状况仍然充满信心。强生制药研发全球主管Mathai Mammen表示：“使用强生疫苗的人的安全和福祉仍然是我们的首要任务。”</blockquote></p><p> He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p><p><blockquote>他表示，该公司将与疾病预防控制中心合作采取下一步措施，并强烈支持有关TTS等罕见事件以及如何管理它的教育。</blockquote></p><p> J&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p><p><blockquote>强生的Covid-19疫苗基于与辉瑞和Moderna疫苗中使用的信使RNA不同的技术。</blockquote></p><p> J&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p><p><blockquote>强生的疫苗包括一种可导致普通感冒的无害版本的病毒，该病毒被设计成包含引发针对冠状病毒的免疫反应的基因指令。mRNA疫苗不含任何病毒物质，并使用不同的方式传递遗传密码，引发针对冠状病毒的免疫反应。</blockquote></p><p> Earlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p><p><blockquote>今年早些时候，联邦卫生当局在调查TTS病情时暂停了强生疫苗的使用。在卫生当局得出结论认为疫苗的益处仍然大于风险后，该疫苗的使用于四月份恢复。</blockquote></p><p> The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p><p><blockquote>为CDC提供疫苗政策建议的ACIP在召开两次会议讨论该问题后，于4月份投票决定恢复使用强生的疫苗。向疫苗提供者和接受者提供的情况说明书中添加了有关风险的警告，包括30至49岁女性的风险似乎最高。</blockquote></p><p> At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p><p><blockquote>当时，在接种的近700万剂疫苗中，共报告了15例TTS病例。所有病例均发生在18至59岁的女性中，中位年龄为37岁。接种疫苗后6至15天出现症状。</blockquote></p><p> As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p><p><blockquote>截至8月31日，CDC官员在顾问会议上表示，在所有接种者中，每接种100万剂强生疫苗，就会报告约3.8例TTS病例。30至39岁女性的比率最高，为每百万剂10.6剂。</blockquote></p><p> CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p><p><blockquote>CDC官员还表示，在那些患TTS的人中，死亡率约为15%。官员称，死者入院后病情迅速恶化。</blockquote></p><p> CDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p><p><blockquote>CDC官员表示，接种强生的疫苗仍然优于不接种疫苗，但辉瑞-BioNTech和Moderna的信使RNA疫苗的益处和风险之间的平衡优于强生。与今年早些时候不同，美国目前的mRNA疫苗供应充足。</blockquote></p><p> A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p><p><blockquote>ACIP的建议对疫苗提供者或接受者没有约束力，但它将具有重大影响力，因为该委员会很少表达对一种疫苗的偏好。</blockquote></p><p> Some committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p><p><blockquote>一些委员会成员表示，J&J疫苗应该继续提供给无法接种mRNA疫苗的人。</blockquote></p><p> Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p><p><blockquote>卫生官员表示，对mRNA疫苗中的成分过敏的人，或对一定剂量的疫苗有严重过敏反应的人，不应接种这些疫苗。</blockquote></p><p> The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p><p><blockquote>mRNA疫苗也有引起包括心肌炎在内的心脏炎症的风险，特别是在30岁以下的男性中。然而卫生官员表示，预防Covid-19住院和死亡的好处超过了心肌炎的风险。</blockquote></p><p></p><p> Penny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p><p><blockquote>强生疫苗全球治疗领域负责人Penny Heaton告诉委员会成员，该公司一直在监测疫苗的安全性，包括TTS风险。她说，这种疫苗是拯救生命的工具，该公司正在世界各地供应数亿剂疫苗。</blockquote></p><p> Partly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p><p><blockquote>部分出于安全考虑，强生的单剂疫苗的使用量远低于Moderna和辉瑞及其合作伙伴BioNTech SE的两剂疫苗。</blockquote></p><p> About 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.</p><p><blockquote>据CDC称，美国约有1610万人接种了强生疫苗。强生疫苗已接种约87万剂加强剂。</blockquote></p><p> More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p><p><blockquote>在美国，超过1.13亿人接种了两剂辉瑞-BioNTech疫苗，超过7200万人接种了两剂Moderna疫苗。根据疾病预防控制中心的数据，美国已经注射了超过3000万剂辉瑞疫苗和2400万剂Moderna加强剂。</blockquote></p><p> J&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.</p><p><blockquote>强生周四表示，最近更新了其疫苗的情况说明书，称不应将其注射给在接受过先前剂量的强生疫苗或其他具有类似腺病毒设计的疫苗后曾出现TTS的人。</blockquote></p><p> Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p><p><blockquote>其他具有类似设计的疫苗包括阿斯利康公司的Covid-19疫苗，该疫苗在美国以外有售，但在美国没有。</blockquote></p><p> The recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.</p><p><blockquote>该建议可能会影响美国以外对强生疫苗的支持，包括在努力增加剂量供应的国家，就在强生开始运送默克公司帮助生产的疫苗之际。</blockquote></p><p> The CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.</p><p><blockquote>CDC咨询委员会成员没有考虑反对使用强生疫苗的建议，部分原因是此举可能会削弱人们对强生疫苗的信心，而不是mRNA疫苗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154960652","content_text":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.\n\nThe Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.\n\nThe updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.\n\nThere have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.\n\nThe rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.\n\n“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.\n\nJ&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.\n\nHe said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.\n\nJ&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.\n\nJ&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.\n\nEarlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.\n\nThe ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.\nAt that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.\n\nAs of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.\n\nCDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.\n\nCDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.\n\nA recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.\n\n\nSome committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.\n\nHealth officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.\n\nThe mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.\n\nPenny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.\n\nPartly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.\n\nAbout 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.\n\nMore than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.\n\nJ&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.\n\nOther shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.\n\nThe recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.\n\nThe CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.","news_type":1,"symbols_score_info":{"PFE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2444,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690543539"}
精彩评论